SCHEMBL2398099

SCHEMBL2398099

CNS(=O)(=O)c1ccc(-c2sc(Nc3cnccn3)nc2C)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
PIK3CD O00329 8/20 0.44
PIK3CB P42338 8/20 0.44
PIK3CA P42336 7/20 0.44
PIK3CG P48736 7/20 0.44
CCNT1 O60563 6/20 0.40
CCNA2 P20248 6/20 0.40
CDK2 P24941 6/20 0.40
CDK9 P50750 6/20 0.40
CCNA1 P78396 6/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2396335 0.89 PIK3CD (0.57) MEN1KMT2APIK3CDPIK3CBPIK3CA
SCHEMBL2395910 0.88 MEN1 (0.60) MEN1KMT2APIK3CDPIK3CBPIK3CA
SCHEMBL2395311 0.86 PIK3C2G (0.42) MEN1KMT2APIK3CDPIK3CBPIK3CA
SCHEMBL1888443 0.82 NPC1 (0.48) MEN1KMT2APIK3CDPIK3CBPIK3CA
SCHEMBL2393257 0.82 MEN1 (0.43) MEN1KMT2APIK3CDPIK3CBPIK3CA
SCHEMBL2395755 0.80 MEN1 (0.60) MEN1KMT2APIK3CDPIK3CBPIK3CA
SCHEMBL2400510 0.80 MEN1 (0.41) MEN1KMT2APIK3CDPIK3CBPIK3CA
SCHEMBL2394625 0.79 KMT2A (0.43) MEN1KMT2APIK3CDPIK3CBPIK3CA
SCHEMBL2397191 0.78 KDR (0.45) MEN1KMT2APIK3CDPIK3CBPIK3CA
SCHEMBL2399934 0.78 MEN1 (0.53) MEN1KMT2APIK3CDPIK3CBPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017608-B2 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2011-09-13 US disclosed
EP-1608647-B1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-09 EP disclosed
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2006-07-06 US disclosed
EP-1608647-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS Novartis AG (CH) 2005-12-28 EP disclosed
WO-2004078754-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors MAP3K13, AKT3, MAP3K3 MEN1 1758/4885KMT2A 2160/4885PIK3CD 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.